Cited by 602HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual RiskHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.

Open access

Liu, Albert Y., Cohen, Stephanie E., Vittinghoff, Eric, Anderson, Peter L., Doblecki-Lewis, Susanne, Bacon, Oliver, Chege, Wairimu, Postle, Brian S., Matheson, Tim, Amico, K. Rivet, Liegler, Teri, Rawlings, M. Keith, Trainor, Nikole, Blue, Robert Wilder, Estrada, Yannine, Coleman, Megan E., Cardenas, Gabriel, Feaster, Daniel J., Grant, Robert, Philip, Susan S., Elion, Richard, Buchbinder, Susan, Kolber, Michael A.·2016·JAMA Internal Medicine

DOI 10.1001/jamainternmed.2015.4683PMC PMC5042323

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Several randomized clinical trials have demonstrated the efficacy of preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM). OBJECTIVE: To assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States. DESIGN, SETTING, AND PARTICIPANTS: Demonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015. INTERVENTIONS: A combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks. All participants received HIV testing, brief client-centered counseling, and clinical monitoring. MAIN OUTCOMES AND MEASURES: Concentrations of tenofovir diphosphate in dried blood spot samples, self-reported numbers of anal sex partners and episodes of condomless receptive anal sex, and incidence of STI and HIV acquisition. RESULTS: Overall, 557 participants initiated PrEP, and 437 of these (78.5%) were retained through 48 weeks. Based on the findings from the 294 participants who underwent measurement of tenofovir diphosphate levels, 80.0% to 85.6% had protective levels (consistent with ≥4 doses/wk) at follow-up visits. African American participants (56.8% of visits; P = .003) and those from the Miami site (65.1% of visits; P < .001) were less likely to have protective levels, whereas those with stable housing (86.8%; P = .02) and those reporting at least 2 condomless anal sex partners in the past 3 months (88.6%; P = .01) were more likely to have protective levels. The mean number of anal sex partners declined during follow-up from 10.9 to 9.3, whereas the proportion engaging in condomless receptive anal sex remained stable at 65.5% to 65.6%. Overall STI incidence was high (90 per 100 person-years) but did not increase over time. Two individuals became HIV infected during follow-up (HIV incidence, 0.43 [95% CI, 0.05-1.54] infections per 100 person-years); both had tenofovir diphosphate levels consistent with fewer than 2 doses/wk at seroconversion. CONCLUSIONS AND RELEVANCE: The incidence of HIV acquisition was extremely low despite a high incidence of STIs in a large US PrEP demonstration project. Adherence was higher among those participants who reported more risk behaviors. Interventions that address racial and geographic disparities and housing instability may increase the impact of PrEP.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamainternmed.2015.4683

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
The Patient Health Questionnaire-2: Validity of a Two-Item Depression Screener
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000093487.78664.3c · Cited by 6,359
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapía, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,229
Regression models for ordinal responses: a review of methods and applications
Ananth, C. V. (1997) · International Journal of Epidemiology · doi:10.1093/ije/26.6.1323 · Cited by 594
Diagnoses of HIV infection in the United States and dependent areas, 2012
Siddiqi, A.-E.-A., Cohen, S. M., Johnson, A. S., Hu, X., Li, J., Patala, A., Wu, B., Guo, X., Dasari, S. R., Hall, I., et al. (2014) · Cited by 429

Show all 46 references

Research works printed but not linked: 6

[4]McCormack S Dunn D Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study [Abstract 22LB] Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA February 23-26, 2015
[5]Molina JM Capitant C Spire B On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial [Abstract 24LB] Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA February 23-26, 2015 2015
[40]Liu A Developing and Implementing a Mobile Health (mHealth) Adherence Support System for HIV-Uninfected Men who have Sex with Men (MSM) Taking Pre-Exposure Prophylaxis (PrEP): The iText Study 8th International Conference on HIV Treatment and Prevention Adherence; [AB 229] Miami, FL June 2-4, 2013
[42]Scott H Vittinghoff E Irvin R Sex Pro: A Personalized HIV Risk Assessment Tool for Men Who Have Sex With Men [Abstract 1017] Conference on Retroviruses and Opportunistic Infections (CROI) Seattle, WA February 23-26, 2015
[43]Vallabhaneni S Hartogensis W Sheon N Harnessing mobile health technology in HIV research: a pilot study utilizing a smartphone-based daily-diary app to collect event-level sexual activity data [Abstract TUPE358] 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention 2013 Kuala Lampur, Malaysia
[46]Cohen SE Vittinghoff E Doblecki-Lewis S Response to “Race and the public health impact potential of PrEP in the United States” J Acquir Immune Defic Syndr 2015 PMC4558271 26049284

Sorted by citations

Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D. C. W., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 776
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Günthard, H. F., Saag, M. S., Benson, C. A., del Rı́o, C., Eron, J. J., Gallant, J. E., Hoy, J., Mugavero, M. J., Sax, P. E., Thompson, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 740
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
Molina, J.-M., Charreau, I., Chidiac, C., Pialoux, G., Cua, E., Delaugerre, C., Capitant, C., Rojas-Castro, D., Fonsart, J., Bercot, B., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30725-9 · Cited by 449
Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.
Traeger, M. W., Schroeder, S. E., Wright, E. J., Hellard, M. E., Cornelisse, V. J., Doyle, J. S., & Stoové, M. A. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy182 · Cited by 447
Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection
Traeger, M. W., Cornelisse, V. J., Asselin, J., Price, B., Roth, N. J., Willcox, J., Tee, B. K., Fairley, C. K., Chang, C. C., Armishaw, J., et al. (2019) · JAMA · doi:10.1001/jama.2019.2947 · Cited by 427
The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States
Siegler, A. J., Mouhanna, F., Mera, R. M., Weiss, K. M., Pembleton, E. S., Guest, J. L., Jones, J. S., Castel, A. D., Yeung, H., Kramer, M. R., et al. (2018) · Annals of Epidemiology · doi:10.1016/j.annepidem.2018.06.005 · Cited by 413
An Update on the Global Epidemiology of Syphilis
Kojima, N., & Klausner, J. D. (2018) · Current Epidemiology Reports · doi:10.1007/s40471-018-0138-z · Cited by 410
Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition — United States, 2015
Smith, D. K., Handel, M. M. V., Wolitski, R. J., Stryker, J. E., Hall, H. I., Prejean, J., Koenig, L. J., & Valleroy, L. A. (2015) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6446a4 · Cited by 355
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312
Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation
Marcus, J. L., Hurley, L. B., Hare, C. B., Nguyen, D. P., Phengrasamy, T., Silverberg, M. J., Stoltey, J. E., & Volk, J. E. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001129 · Cited by 290
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy
Anderson, P. L., Liu, A., Castillo‐Mancilla, J., Gardner, E. M., Seifert, S. M., McHugh, C., Wagner, T. M., Campbell, K. M., Morrow, M., Ibrahim, M. E., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01710-17 · Cited by 276
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek, S., Rudy, B. J., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rutledge, B. N., Liu, N., Brothers, J., Mulligan, K. M., Zimet, G. D., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001179 · Cited by 275
Preexposure Prophylaxis for the Prevention of HIV Infection
Chou, R., Evans, C., Hoverman, A. S., Sun, C. J., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019) · JAMA · doi:10.1001/jama.2019.2591 · Cited by 275
HIV Preexposure Prophylaxis
Riddell, J., Amico, K. R., & Mayer, K. H. (2018) · JAMA · doi:10.1001/jama.2018.1917 · Cited by 265
Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review
Pleuhs, B., Quinn, K. G., Walsh, J. L., Petroll, A. E., & John, S. A. (2020) · AIDS Patient Care and STDs · doi:10.1089/apc.2019.0189 · Cited by 260
A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?
Sidebottom, D. B., Ekström, A. M., & Strömdahl, S. K. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3463-4 · Cited by 258
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis
Zhang, J., Li, C., Xu, J., Hu, Z., Rutstein, S. E., Tucker, J. D., Ong, J. J., Jiang, Y., Geng, W., Wright, S. T., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00030-3 · Cited by 238
Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi
Arnold, T. L., Brinkley‐Rubinstein, L., Chan, P. A., Perez‐Brumer, A., Bologna, E. S., Beauchamps, L. S., Johnson, K. L., Mena, L. A., & Nunn, A. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172354 · Cited by 239
Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study.
Jenness, S. M., Weiss, K. M., Goodreau, S. M., Gift, T., Chesson, H., Hoover, K. W., Smith, D. K., Liu, A. Y., Sullivan, P. S., & Rosenberg, E. S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix439 · Cited by 224
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States
Hosek, S., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rudy, B. J., Rutledge, B. N., Liu, N., Harris, D. R., Mulligan, K. M., Zimet, G. D., et al. (2017) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2017.2007 · Cited by 223
Retention in care outcomes for HIV pre‐exposure prophylaxis implementation programmes among men who have sex with men in three US cities
Chan, P. A., Mena, L. A., Patel, R. R., Oldenburg, C. E., Beauchamps, L. S., Perez‐Brumer, A., Parker, S., Mayer, K. H., Mimiaga, M. J., & Nunn, A. S. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20903 · Cited by 226
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study
Henrich, T. J., Hatano, H., Bacon, O., Hogan, L. E., Rutishauser, R. L., Hill, A. L., Kearney, M. F., Anderson, E. M., Buchbinder, S., Cohen, S. E., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002417 · Cited by 224
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study
Grinsztejn, B. G. J., Hoagland, B., Moreira, R. I., Kallas, E. G., Madruga, J. V., Goulart, S. P., Leite, I. C., de Freitas, L. A., Martins, L. M. R., Torres, T. S., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30008-0 · Cited by 221
Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men
Kojima, N., Davey, D. J., & Klausner, J. D. (2016) · AIDS · doi:10.1097/qad.0000000000001185 · Cited by 194
Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States
Jenness, S. M., Goodreau, S. M., Rosenberg, E. S., Beylerian, E. N., Hoover, K. W., Smith, D. K., & Sullivan, P. S. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw223 · Cited by 203
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Landovitz, R. J., Li, S., Grinsztejn, B. G. J., Dawood, H., Liu, A., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L. M., Chau, G., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002690 · Cited by 184
Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study
Hoornenborg, E., Coyer, L., Achterbergh, R., Matser, A. A., van der Loeff, M. F. S., Boyd, A. C., van Duijnhoven, Y. T. H. P., Bruisten, S. M., Oostvogel, P. M., Davidovich, U., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30136-5 · Cited by 168
Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review and Meta-analysis
Ong, J. J., Baggaley, R. C., Wi, T. E., Tucker, J. D., Fu, H., Smith, M. K., Rafael, S., Anglade, V., Falconer, J., Ofori-Asenso, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17134 · Cited by 173
HIV Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex with Men in a Community-Based Sexual Health Clinic
Hojilla, J. C., Vlahov, D., Crouch, P.-C., Dawson-Rose, C. S., Freeborn, K., & Carrico, A. W. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-2009-x · Cited by 166
The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices
Sevelius, J. M., Deutsch, M. B., & Grant, R. M. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.7.21105 · Cited by 167
Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV
Nguyen, V., Greenwald, Z. R., Trottier, H., Cadieux, M., Goyette, A., Beauchemin, M., Charest, L., Longpré, D., Lavoie, S., Tossa, H. G., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001718 · Cited by 167
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study
Liu, A., Vittinghoff, E., von Felten, P., Amico, K. R., Anderson, P. L., Lester, R. T., Andrew, E. V. W., Estes, I., Serrano, P. A., Brothers, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy810 · Cited by 157
Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring
Castillo‐Mancilla, J., & Haberer, J. E. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0377-0 · Cited by 144
Prevention, treatment and cure of HIV infection
Landovitz, R. J., Scott, H. M., & Deeks, S. G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00914-1 · Cited by 153
Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States
Mayer, K. H., Chan, P. A., Patel, R. R., Flash, C. A., & Krakower, D. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001579 · Cited by 146
High pre‐exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project
Hoagland, B., Moreira, R. I., Boni, R. B. D., Kallas, E. G., Madruga, J. V., Vasconcelos, R. D. P., Goulart, S. P., Torres, T. S., Marins, L. M. S., Anderson, P. L., et al. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21472 · Cited by 142
The PrEP Care Continuum and Black Men Who Have Sex with Men: A Scoping Review of Published Data on Awareness, Uptake, Adherence, and Retention in PrEP Care
Ezennia, O., Geter, A., & Smith, D. K. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02641-2 · Cited by 136
MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection.
Hoornenborg, E., Achterbergh, R. C. A., Schim van der Loeff, M. F., Davidovich, U., Hogewoning, A., de Vries, H. J. C., Schinkel, J., Prins, M., & van de Laar, T. J. W. (2017) · AIDS · doi:10.1097/qad.0000000000001522 · Cited by 137
Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study
Storholm, E. D., Volk, J. E., Marcus, J. L., Silverberg, M. J., & Satre, D. D. (2017) · Prevention Science · doi:10.1007/s11121-017-0799-8 · Cited by 147
Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions
Spinelli, M. A., Haberer, J. E., Chai, P. R., Castillo‐Mancilla, J., Anderson, P. L., & Gandhi, M. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00502-5 · Cited by 146
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots
Zheng, J., Rower, C., McAllister, K. J., Castillo‐Mancilla, J., Klein, B., Meditz, A. L., Guida, L., Kiser, J. J., Bushman, L. R., & Anderson, P. L. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.01.038 · Cited by 134
Recent advances in pre-exposure prophylaxis for HIV
Desai, M., Field, N. M., Grant, R. M., & McCormack, S. (2017) · BMJ · doi:10.1136/bmj.j5011 · Cited by 136
Iowa TelePrEP: A Public-Health-Partnered Telehealth Model for Human Immunodeficiency Virus Preexposure Prophylaxis Delivery in a Rural State
Hoth, A. B., Shafer, C., Dillon, D., Mayer, R., Walton, G., & Ohl, M. (2019) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001017 · Cited by 131
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men
Greene, G. J., Swann, G., Fought, A. J., Carballo‐Diéguez, A., Hope, T. J., Kiser, P. F., Mustanski, B. S., & D’Aquila, R. T. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1565-9 · Cited by 127
Challenges in Translating PrEP Interest Into Uptake in an Observational Study of Young Black MSM
Rolle, C.-P., Rosenberg, E. S., Siegler, A. J., Sanchez, T., Luisi, N., Weiss, K. M., Cutro, S. R., del Rı́o, C., Sullivan, P. S., & Kelley, C. F. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001497 · Cited by 131
Persistence on HIV preexposure prophylaxis medication over a 2‐year period among a national sample of 7148 PrEP users, United States, 2015 to 2017
Coy, K. C., Hazen, R. J., Kirkham, H. S., Delpino, A., & Siegler, A. J. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25252 · Cited by 132
Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis
Werner, R. N., Gaskins, M. D., Nast, A., & Dressler, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208107 · Cited by 118
Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users
Lal, L., Audsley, J., Murphy, D., Fairley, C. K., Stoove, M. A., Roth, N., Moore, R. D., Tee, B. K., Puratmaja, N., Anderson, P. L., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001519 · Cited by 122
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial
Bekker, L., Roux, S., Sebastien, E., Yola, N., Amico, K. R., Hughes, J. P., Marzinke, M. A., Hendrix, C. W., Anderson, P. L., Elharrar, V., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30156-x · Cited by 119
Da evidência à ação: desafios do Sistema Único de Saúde para ofertar a profilaxia pré-exposição sexual (PrEP) ao HIV às pessoas em maior vulnerabilidade
Zucchi, E. M., Grangeiro, A., Ferraz, D., Pinheiro, T. F., Alencar, T., Ferguson, L., Estevam, D. L., & Munhoz, R. (2018) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00206617 · Cited by 130
An Information–Motivation–Behavioral Skills Model of PrEP Uptake
Dubov, A., Altice, F. L., & Fraenkel, L. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2095-4 · Cited by 113
Pre‐exposure prophylaxis initiation and adherence among Black men who have sex with men ( MSM ) in three US cities: results from the HPTN 073 study
Wheeler, D. P., Fields, S. D., Beauchamp, G. G., Chen, Y. Q., Emel, L., Hightow‐Weidman, L., Hucks‐Ortiz, C., Kuo, I. C., Lucas, J. P., Magnus, M., et al. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25223 · Cited by 109
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care
Silapaswan, A., Krakower, D., & Mayer, K. H. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3899-4 · Cited by 109
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study
Nichols, B. E., Boucher, C. A., van der Valk, M., Rijnders, B. J. A., & van de Vijver, D. A. M. C. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30311-5 · Cited by 107
Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study
Jourdain, H., de Gage, S. B., Desplas, D., & Dray‐Spira, R. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(22)00106-2 · Cited by 111
Addressing Gaps in HIV Preexposure Prophylaxis Care to Reduce Racial Disparities in HIV Incidence in the United States
Jenness, S. M., Maloney, K. M., Smith, D. K., Hoover, K. W., Goodreau, S. M., Rosenberg, E. S., Weiss, K. M., Liu, A., Rao, D. W., & Sullivan, P. S. (2018) · American Journal of Epidemiology · doi:10.1093/aje/kwy230 · Cited by 105
Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System
Hojilla, J. C., Hurley, L. B., Marcus, J. L., Silverberg, M. J., Skarbinski, J., Satre, D. D., & Volk, J. E. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22692 · Cited by 102
Projected HIV and Bacterial Sexually Transmitted Infection Incidence Following COVID-19–Related Sexual Distancing and Clinical Service Interruption
Jenness, S. M., Guillou, A. L., Chandra, C., Mann, L. M., Sanchez, T., Westreich, D. J., & Marcus, J. L. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab051 · Cited by 101
Sexually transmitted infections and pre-exposure prophylaxis: challenges and opportunities among men who have sex with men in the US
Scott, H. M., & Klausner, J. D. (2016) · AIDS Research and Therapy · doi:10.1186/s12981-016-0089-8 · Cited by 102
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study
Moore, D. J., Jain, S., Dubé, M. P., Daar, E. S., Sun, X., Young, J., Corado, K., Ellorin, E. E., Milam, J. E., Collins, D. O., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1055 · Cited by 100
Integrating HIV Preexposure Prophylaxis With Community-Based Syringe Services for Women Who Inject Drugs: Results From the Project SHE Demonstration Study
Roth, A. M., Tran, N. K., Felsher, M. A., Gadegbeku, A. B., Piecara, B., Fox, R., Krakower, D., Bellamy, S. L., Amico, K. R., Benitez, J., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002558 · Cited by 95
Increased Syphilis Testing of Men Who Have Sex With Men: Greater Detection of Asymptomatic Early Syphilis and Relative Reduction in Secondary Syphilis
Chow, E. P. F., Callander, D., Fairley, C. K., Zhang, L., Donovan, B. J., Guy, R., Lewis, D. A., Hellard, M. E., Read, P. J., Ward, A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix326 · Cited by 94
Men who have sex with men more often chose daily than event‐driven use of pre‐exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam
Hoornenborg, E., Achterbergh, R., van der Loeff, M. F. S., Davidovich, U., van der Helm, J. J., Hogewoning, A. A., van Duijnhoven, Y. T., Sonder, G. J. B., de Vries, H. J. C., Prins, M., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25105 · Cited by 90
Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018
Siegler, A. J., Mehta, C. C., Mouhanna, F., Mera, R. M., Castel, A. D., Pembleton, E. S., Jaggi, C., Jones, J. S., Kramer, M. R., McGuinness, P., et al. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.03.013 · Cited by 91
The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study
Mitchell, K. M., Dimitrov, D., Silhol, R., Geidelberg, L., Moore, M., Liu, A., Beyrer, C., Mayer, K. H., Baral, S., & Boily, M. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00022-9 · Cited by 90
Syndemics and the PrEP Cascade: Results from a Sample of Young Latino Men Who Have Sex with Men
Blashill, A. J., Brady, J. P., Rooney, B. M., Rodríguez-Díaz, C. E., Horvath, K. J., Blumenthal, J. S., Morris, S., Moore, D. J., & Safren, S. A. (2019) · Archives of Sexual Behavior · doi:10.1007/s10508-019-01470-7 · Cited by 93
The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review
Vanhamel, J., Rotsaert, A., Reyniers, T., Nöstlinger, C., Laga, M., Landeghem, E. V., & Vuylsteke, B. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05568-w · Cited by 89
Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): Findings from a large cohort of gay and bisexual men in the U.S.
Rendina, H. J., Whitfield, T. H. F., Grov, C., Starks, T. J., & Parsons, J. T. (2016) · Social Science & Medicine · doi:10.1016/j.socscimed.2016.10.030 · Cited by 91
Confronting Rising STIs in the Era of PrEP and Treatment as Prevention
Ramchandani, M. S., & Golden, M. R. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00446-5 · Cited by 84
Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings
Marcus, J. L., Volk, J. E., Pinder, J., Liu, A., Bacon, O., Hare, C. B., & Cohen, S. E. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0308-x · Cited by 89
Implementation of Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention Among Men Who Have Sex With Men at a New England Sexually Transmitted Diseases Clinic
Chan, P. A., Glynn, T. R., Oldenburg, C. E., Montgomery, M. C., Robinette, A., Almonte, A. A., Raifman, J., Mena, L. A., Patel, R. R., Mayer, K. H., et al. (2016) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000514 · Cited by 87
Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections
Castillo‐Mancilla, J., Morrow, M., Coyle, R. P., Coleman, S. S., Gardner, E. M., Zheng, J., Ellison, L., Bushman, L. R., Kiser, J. J., MaWhinney, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy708 · Cited by 86
Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care
Kamis, K. F., Marx, G. E., Scott, K. A., Gardner, E. M., Wendel, K. A., Scott, M., Montgomery, A. E., & Rowan, S. E. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz310 · Cited by 84
Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S.
Garrison, L. E., & Haberer, J. E. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.04.036 · Cited by 89
A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis
Fuchs, J. D., Stojanovski, K., Vittinghoff, E., McMahan, V., Hosek, S., Amico, K. R., Kouyate, A., Gilmore, H. J., Buchbinder, S., Lester, R. T., et al. (2018) · AIDS Patient Care and STDs · doi:10.1089/apc.2017.0255 · Cited by 86
HIV pre-exposure prophylaxis for women
Sheth, A. N., Rolle, C.-P., & Gandhi, M. (2016) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30458-1 · Cited by 87
Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation
Sullivan, P. S., & Siegler, A. J. (2018) · Sexual Health · doi:10.1071/sh18103 · Cited by 83
Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012–2017
Huang, Y.-L. A., Tao, G., Smith, D. K., & Hoover, K. W. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa037 · Cited by 83
Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State
Seifert, S. M., Chen, X., Meditz, A. L., Castillo‐Mancilla, J., Gardner, E. M., Predhomme, J. A., Clayton, C., Austin, G. L., Palmer, B. E., Zheng, J., et al. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0008 · Cited by 83
Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project
Doblecki‐Lewis, S., Liu, A., Feaster, D. J., Cohen, S. E., Cardenas, G. A., Bacon, O., Andrew, E. V. W., & Kolber, M. A. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001236 · Cited by 83
Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use
Hoornenborg, E., Coyer, L., van Laarhoven, A., Achterbergh, R., de Vries, H. J. C., Prins, M., & van der Loeff, M. F. S. (2018) · AIDS · doi:10.1097/qad.0000000000001874 · Cited by 80
Is Screening for Chlamydia and Gonorrhea in Men Who Have Sex With Men Associated With Reduction of the Prevalence of these Infections? A Systematic Review of Observational Studies
Tsoumanis, A., Hens, N., & Kenyon, C. R. (2018) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000824 · Cited by 82
Growth in Proportion and Disparities of HIV PrEP Use Among Key Populations Identified in the United States National Goals: Systematic Review and Meta-analysis of Published Surveys
Kamitani, E., Johnson, W. D., Wichser, M. E., Adegbite, A. H., Mullins, M. M., & Sipe, T. A. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002345 · Cited by 79
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting
Montgomery, M. C., Oldenburg, C. E., Nunn, A. S., Mena, L. A., Anderson, P. L., Liegler, T. J., Mayer, K. H., Patel, R. R., Almonte, A. A., & Chan, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157742 · Cited by 80
Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China
Zhang, L., Peng, P., Wu, Y., Ma, X., Soe, N. N., Huang, X., Wu, H., Markowitz, M. H., & Meyers, K. A. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2205-3 · Cited by 78
Motives for choosing, switching and stopping daily or event‐driven pre‐exposure prophylaxis – a qualitative analysis
Zimmermann, H. M. L., Eekman, S. W., Achterbergh, R., van der Loeff, M. F. S., Prins, M., de Vries, H. J. C., Hoornenborg, E., & Davidovich, U. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25389 · Cited by 80
The “Safe Sex” Conundrum: Anticipated Stigma From Sexual Partners as a Barrier to PrEP Use Among Substance Using MSM Engaging in Transactional Sex
Biello, K. B., Oldenburg, C. E., Mitty, J. A., Closson, E. F., Mayer, K. H., Safren, S. A., & Mimiaga, M. J. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1466-y · Cited by 79
Behavioral changes following uptake of HIV pre-exposure prophylaxis among men who have sex with men in a clinical setting.
Oldenburg, C. E., Nunn, A. S., Montgomery, M., Almonte, A., Mena, L., Patel, R. R., Mayer, K. H., & Chan, P. A. (2018) · AIDS and Behavior · doi:10.1007/s10461-017-1701-1 · Cited by 76
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
Glidden, D. V., Mulligan, K. M., McMahan, V., Anderson, P. L., Guanira, J. V., Chariyalertsak, S., Buchbinder, S., Bekker, L., Schechter, M., Grinsztejn, B. G. J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy083 · Cited by 79
Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics
Scott, H. M., Spinelli, M. A., Vittinghoff, E., Morehead-Gee, A., Hirozawa, A. M., James, C., Hammer, H., Liu, A., Gandhi, M., & Buchbinder, S. (2019) · AIDS · doi:10.1097/qad.0000000000002347 · Cited by 76
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis
Markowitz, M. H., Grossman, H. A., Anderson, P. L., Grant, R. M., Gandhi, M., Horng, H., & Mohri, H. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001534 · Cited by 75
Alignment of adherence and risk for HIV acquisition in a demonstration project of pre‐exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention‐effective adherence
Haberer, J. E., Kidoguchi, L., Heffron, R. A., Mugo, N., Bukusi, E. A., Katabira, E. T., Asiimwe, S. B., Thomas, K. K., Celum, C., & Baeten, J. M. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.21842 · Cited by 73
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California
Landovitz, R. J., Beymer, M. R., Kofron, R., Amico, K. R., Psaros, C., Bushman, L. R., Anderson, P. L., Flynn, R. P., Lee, D. P., Bolan, R., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001538 · Cited by 75
Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network
Spinelli, M. A., Scott, H. M., Vittinghoff, E., Liu, A., Gonzalez, R., Morehead-Gee, A., Gandhi, M., & Buchbinder, S. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz101 · Cited by 73
Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence
John, S. A., Rendina, H. J., Grov, C., & Parsons, J. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189794 · Cited by 71
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines
Wright, E., Grulich, A. E., Roy, K., Boyd, M. A., Cornelisse, V. J., Russell, D. B., O’Donnell, D., Whittaker, B., Crooks, L., & Zablotska, I. (2017) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30338-1 · Cited by 71
Pharmacy-Based Interventions to Increase Use of HIV Pre-exposure Prophylaxis in the United States: A Scoping Review
Zhao, A., Dangerfield, D. T., Nunn, A. S., Patel, R. R., Farley, J. E., Ugoji, C. C., & Dean, L. T. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03494-4 · Cited by 70
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing
Castillo‐Mancilla, J., Seifert, S. M., Campbell, K. M., Coleman, S. S., McAllister, K. J., Zheng, J., Gardner, E. M., Liu, A., Glidden, D. V., Grant, R. M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01017-16 · Cited by 70

Authors: Liu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., Liegler, T., Rawlings, M. K., Trainor, N., Blue, R. W., Estrada, Y., Coleman, M. E., Cardenas, G., Feaster, D. J., Grant, R., Philip, S. S., Elion, R., Buchbinder, S., & Kolber, M. A.
Affiliations: University of California, San Francisco (US)
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora
Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida
National Institutes of Health (US)
DF/Net Research, Inc, Seattle, Washington
San Francisco Department of Public Health (US)
University of Michigan (US)
Gilead Sciences (United States) (US)
University of Miami (US)
Whitman-Walker Health (US)
Gladstone Institutes (US)
George Washington University (US)
Corresponding author: Liu, Albert Y.
ORCID: Liu, Albert Y.
Cohen, Stephanie E.
Vittinghoff, Eric
Anderson, Peter L.
Bacon, Oliver
Chege, Wairimu
Matheson, Tim
Amico, K. Rivet
Rawlings, M. Keith
Estrada, Yannine
Coleman, Megan E.
Feaster, Daniel J.
Grant, Robert
Philip, Susan S.
Buchbinder, Susan
Kolber, Michael A.
Venue: JAMA Internal Medicine
Publisher: American Medical Association (AMA)
Published: 2016-01-01
Volume: 176
Issue: 1
Pages: 75
ISSN: 2168-6106 (ISSN-L)
DOI: 10.1001/jamainternmed.2015.4683
PMC: PMC5042323
OpenAlex: W2173821673
Cited by: 602
References: 46
Citations by year: 2026: 12 · 2025: 29 · 2024: 42 · 2023: 45 · 2022: 57 · 2021: 47 · 2020: 68 · 2019: 87 · 2018: 83 · 2017: 71 · 2016: 57
FWCI: 55.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Internal Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health
National Institute of Mental Health (R01MH095628)
National Institute of Allergy and Infectious Diseases (R01AI118575, UM1AI069496, P30AI027763, P30AI073961)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords: pre-exposure prophylaxis, HIV prevention, men who have sex with men, transgender women, tenofovir disoproxil fumarate, emtricitabine, PrEP adherence, sexually transmitted infections, sexual partners, HIV acquisition, HIV testing, community health centers, STD clinics, housing stability
MeSH terms: Tenofovir, Assessment of Medication Adherence, Adenine, Adolescent, Adult, Bisexuality, Chlamydia Infections, Community Health Services, District of Columbia, Female, Florida, Gonorrhea, Humans, Male, Middle Aged, Organophosphates, Prospective Studies, San Francisco, Sexual Behavior, Syphilis, HIV Infections, Drug Monitoring, Homosexuality, Male, Anti-HIV Agents, Unsafe Sex, Medication Adherence, Young Adult, Reproductive Health, Transgender Persons, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks